Curbstone Financial Management Corp increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 162.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 4,686 shares of the medical equipment provider’s stock after acquiring an additional 2,903 shares during the period. Curbstone Financial Management Corp’s holdings in Zimmer Biomet Holdings were worth $549,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Lord Abbett & CO. LLC grew its holdings in shares of Zimmer Biomet Holdings by 2.8% during the 2nd quarter. Lord Abbett & CO. LLC now owns 43,400 shares of the medical equipment provider’s stock worth $5,573,000 after purchasing an additional 1,200 shares in the last quarter. United Bank VA acquired a new stake in shares of Zimmer Biomet Holdings during the 2nd quarter worth approximately $2,131,000. WFG Advisors LP grew its holdings in shares of Zimmer Biomet Holdings by 46,690.0% during the 2nd quarter. WFG Advisors LP now owns 4,679 shares of the medical equipment provider’s stock worth $601,000 after purchasing an additional 4,669 shares in the last quarter. Toronto Dominion Bank lifted its position in shares of Zimmer Biomet Holdings by 25.6% during the 2nd quarter. Toronto Dominion Bank now owns 68,154 shares of the medical equipment provider’s stock worth $8,749,000 after buying an additional 13,891 shares during the period. Finally, Advisory Services Network LLC lifted its position in shares of Zimmer Biomet Holdings by 1.0% during the 2nd quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock worth $474,000 after buying an additional 37 shares during the period. 85.17% of the stock is currently owned by hedge funds and other institutional investors.
ZBH has been the subject of several research analyst reports. Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. BMO Capital Markets reissued a “buy” rating and issued a $136.00 target price on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Wells Fargo & Company reissued a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Morgan Stanley lifted their price objective on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $125.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $136.55.
COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/10/28/zimmer-biomet-holdings-inc-zbh-shares-bought-by-curbstone-financial-management-corp.html.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded up 2.86% during trading on Friday, hitting $124.46. The stock had a trading volume of 1,494,615 shares. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.49. The firm has a 50 day moving average price of $117.60 and a 200-day moving average price of $120.39. The firm has a market capitalization of $25.17 billion, a PE ratio of 35.45 and a beta of 1.19.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by ($0.02). The firm had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.02 earnings per share. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post $8.23 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 22nd were given a dividend of $0.24 per share. The ex-dividend date was Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.77%. Zimmer Biomet Holdings’s payout ratio is 27.59%.
In related news, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.07% of the company’s stock.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.